InsmedINSM
INSM
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 10 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
61% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 44
26% more repeat investments, than reductions
Existing positions increased: 177 | Existing positions reduced: 141
20% more call options, than puts
Call options by funds: $235M | Put options by funds: $197M
7% more funds holding in top 10
Funds holding in top 10: 27 [Q3] → 29 (+2) [Q4]
5% more funds holding
Funds holding: 410 [Q3] → 429 (+19) [Q4]
4% less capital invested
Capital invested by funds: $13.9B [Q3] → $13.3B (-$562M) [Q4]
2.78% less ownership
Funds ownership: 110.39% [Q3] → 107.61% (-2.78%) [Q4]
Research analyst outlook
10 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$90
15%
upside
Avg. target
$99
27%
upside
High target
$110
41%
upside
10 analyst ratings
10 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Jason Zemansky 60% 1-year accuracy 6 / 10 met price target | 23%upside $96 | Buy Maintained | 20 Mar 2025 |
RBC Capital Leonid Timashev 31% 1-year accuracy 13 / 42 met price target | 28%upside $100 | Outperform Reiterated | 19 Mar 2025 |
UBS Trung Huynh 43% 1-year accuracy 3 / 7 met price target | 41%upside $110 | Buy Maintained | 6 Mar 2025 |
Guggenheim Vamil Divan 35% 1-year accuracy 9 / 26 met price target | 30%upside $101 | Buy Reiterated | 25 Feb 2025 |
HC Wainwright & Co. Andrew Fein 31% 1-year accuracy 109 / 356 met price target | 15%upside $90 | Buy Reiterated | 24 Feb 2025 |
Financial journalist opinion
Based on 3 articles about INSM published over the past 30 days
Neutral
Market Watch
3 days ago
Biotech stocks have been hit hard. Why they're a great value now.
Biotech is one of the U.S. stock market's most unloved sectors. But several indicators suggest that a bottom in sentiment could be near, and that's normally a good time to buy.
Neutral
PRNewsWire
5 days ago
Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference
—New Analyses from the Phase 3 ASPEN Study Examining Efficacy and Safety of Brensocatib Across a Variety of Prespecified Subgroups— —Data from ASPEN Post-hoc Analysis Evaluating Changes in Lung Function in Bronchiectasis Patients Who Did or Did Not Experience Pulmonary Exacerbations in the Trial— — Data on Health Status Improvements Over Time Following Culture Conversion in Patients with Mycobacterium Avium Complex (MAC) Lung Disease— BRIDGEWATER, N.J. , March 25, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will present 11 abstracts from across its respiratory portfolio at the American Thoracic Society (ATS) 2025 International Conference, taking place May 18-21, 2025, in San Francisco.
Neutral
PRNewsWire
2 weeks ago
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BRIDGEWATER, N.J. , March 10, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 18 new employees.
Positive
Benzinga
1 month ago
Lung Disease-Focused Insmed 'Is An Attractive Midcap Biotech,' Analyst Says
RBC Capital Markets has initiated coverage on Insmed Inc INSM, citing brensocatib's launch momentum.
Neutral
Zacks Investment Research
1 month ago
International Markets and Insmed (INSM): A Deep Dive for Investors
Examine Insmed's (INSM) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
Neutral
PRNewsWire
1 month ago
Insmed Announces that FDA Does Not Currently Plan to Hold Advisory Committee Meeting to Discuss New Drug Application for Brensocatib in Patients with Bronchiectasis
—FDA Reaffirms Application is Under Priority Review with a PDUFA Target Action Date of August 12, 2025— BRIDGEWATER, N.J. , Feb. 24, 2025 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has informed the Company that it does not currently plan to hold an advisory committee meeting to discuss the New Drug Application (NDA) for brensocatib for patients with non-cystic fibrosis bronchiectasis.
Neutral
Zacks Investment Research
1 month ago
Insmed's Q4 Loss Wider Than Expected, Sales In Line With Estimates
INSM posts wider-than-expected Q4 loss. It reiterates its 2025 sales outlook for Arikayce in the range of $405-$425 million.
Neutral
Seeking Alpha
1 month ago
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Insmed Incorporated (INSM) Q4 2024 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Insmed (INSM) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Negative
Zacks Investment Research
1 month ago
Insmed (INSM) Reports Q4 Loss, Tops Revenue Estimates
Insmed (INSM) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to loss of $1.28 per share a year ago.
Charts implemented using Lightweight Charts™